Published in J Clin Oncol on May 15, 2003
Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE). Nat Biotechnol (2008) 3.43
miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor. Cancer Cell Int (2013) 0.91
Characterization of human mesenchymal stem cells from ewing sarcoma patients. Pathogenetic implications. PLoS One (2014) 0.91
Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib. Virchows Arch (2004) 0.87
Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth. Transl Oncol (2013) 0.84
Targeted therapies for advanced Ewing sarcoma family of tumors. Cancer Treat Rev (2015) 0.81
Flow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcoma. Proc Natl Acad Sci U S A (2015) 0.80
Modeling the initiation of Ewing sarcoma tumorigenesis in differentiating human embryonic stem cells. Oncogene (2015) 0.77
MODELING STROMA-INDUCED DRUG RESISTANCE IN A TISSUE-ENGINEERED TUMOR MODEL OF EWING SARCOMA. Tissue Eng Part A (2016) 0.75
Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs. J Vet Intern Med (2015) 0.75
Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol (2004) 4.46
Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer (2006) 3.11
Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol (2012) 2.67
Chordoma of the mobile spine: fifty years of experience. Spine (Phila Pa 1976) (2006) 2.23
Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet (2013) 2.21
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol (2005) 2.17
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res (2005) 2.09
Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One (2012) 2.06
Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol (2003) 1.99
Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol (2005) 1.94
Vaccines for tumour prevention. Nat Rev Cancer (2006) 1.87
The use of autologous platelet gel to treat difficult-to-heal wounds: a pilot study. Transfusion (2004) 1.80
Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol (2003) 1.79
2011: the immune hallmarks of cancer. Cancer Immunol Immunother (2011) 1.66
Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol (2012) 1.63
Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer (2005) 1.62
Platelet-derived growth factors enhance proliferation of human stromal stem cells. Biomaterials (2003) 1.61
Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics (2009) 1.57
Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res (2011) 1.53
NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res (2010) 1.52
Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer (2014) 1.51
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer (2010) 1.50
Radiographic, CT, and MR imaging features of dedifferentiated chondrosarcomas: a retrospective review of 174 de novo cases. Radiographics (2004) 1.44
In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene (2005) 1.44
Primary angiosarcoma of the parotid gland arising from benign congenital hemangioma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2003) 1.40
Characterization of truncated forms of abnormal prion protein in Creutzfeldt-Jakob disease. J Biol Chem (2008) 1.40
Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support. Virchows Arch (2009) 1.39
Prion protein amyloidosis with divergent phenotype associated with two novel nonsense mutations in PRNP. Acta Neuropathol (2009) 1.39
Brain protein preservation largely depends on the postmortem storage temperature: implications for study of proteins in human neurologic diseases and management of brain banks: a BrainNet Europe Study. J Neuropathol Exp Neurol (2007) 1.38
Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat Genet (2012) 1.37
Clinical outcome of central conventional chondrosarcoma. J Surg Oncol (2012) 1.37
Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol (2007) 1.36
The expression of ccn3(nov) gene in musculoskeletal tumors. Am J Pathol (2002) 1.35
miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol (2012) 1.34
Genetic Creutzfeldt-Jakob disease and fatal familial insomnia: insights into phenotypic variability and disease pathogenesis. Acta Neuropathol (2010) 1.32
Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest (2011) 1.32
Incidence and spectrum of sporadic Creutzfeldt-Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classification. Acta Neuropathol (2009) 1.32
Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. Tumori (2007) 1.31
Imaging findings in desmoplastic fibroma of bone: distinctive T2 characteristics. AJR Am J Roentgenol (2005) 1.29
Phenotypic variability of sporadic human prion disease and its molecular basis: past, present, and future. Acta Neuropathol (2010) 1.29
Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol (2009) 1.28
Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer (2009) 1.26
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res (2004) 1.25
Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma. Clin Cancer Res (2007) 1.25
Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol (2013) 1.21
Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs (2010) 1.21
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer (2009) 1.20
Molecular and cellular biology of rhabdomyosarcoma. Future Oncol (2009) 1.20
Modeling the competition between lung metastases and the immune system using agents. BMC Bioinformatics (2010) 1.19
ImmunoGrid, an integrative environment for large-scale simulation of the immune system for vaccine discovery, design and optimization. Brief Bioinform (2009) 1.19
miRNA expression profile in human osteosarcoma: role of miR-1 and miR-133b in proliferation and cell cycle control. Int J Oncol (2012) 1.18
LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization. Genes Chromosomes Cancer (2009) 1.18
Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin Cancer Res (2005) 1.18
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells. Cancer Res (2004) 1.17
In silico modeling and in vivo efficacy of cancer-preventive vaccinations. Cancer Res (2010) 1.17
Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol (2006) 1.17